ArticleBone & joint research2017
Bisphosphonates and atypical subtrochanteric fractures of the femur.
Article in Bone & joint research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.Journal of the National Cancer Institute · 2020Trial
- Intraoperative Intramedullary Photobiomodulation Therapy for Consolidation of Atypical Femoral Fractures in Elderly Women: A Pilot Study.Journal of stem cells & regenerative medicine · 2026Article
- Sterile Inflammatory Response and Surgery-Related Trauma in Elderly Patients with Subtrochanteric Fractures.Biomedicines · 2024Article
- Current concepts in the management of bisphosphonate associated atypical femoral fractures.World journal of orthopedics · 2021Review
- Evaluation and management of atypical femoral fractures: an update of current knowledge.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2021Review
- Atypical periprosthetic femur fracture on an underestimated atypical femoral pattern. A case report.Trauma case reports · 2021Article
- Immunohistochemical Femoral Nerve Study Following Bisphosphonates Administration.Medicina (Kaunas, Lithuania) · 2020Article
- Bisphosphonate-related Femoral Shaft Fracture.Clinical practice and cases in emergency medicine · 2020Article
- Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide.BMJ case reports · 2019Review
- Risk factors for nonunion after intramedullary nailing of subtrochanteric femoral fractures.Archives of orthopaedic and trauma surgery · 2019Article
- The enigma of atypical femoral fractures: A summary of current knowledge.EFORT open reviews · 2018Article
- A review of atypical subtrochanteric femoral fractures in Northern Ireland between 2010 and 2014.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2018Article
- Article
- The Role of Semipurified Fractions Isolated fromEvidence-based complementary and alternative medicine : eCAM · 2018Article
- A Review on Bone Mineral Density Loss in Total Knee Replacements Leading to Increased Fracture Risk.Clinical reviews in bone and mineral metabolism · 2017Review
- Adult-onset hypophosphatasia diagnosed following bilateral atypical femoral fractures in a 55-year-old woman.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBisphosphonates are widely used as first-line treatment for primary and secondary prevention of fragility fractures. Whilst they have proved effective in this role, there is growing concern over their long-term use, with much evidence linking bisphosphonate-related suppression of bone remodelling to an increased risk of atypical subtrochanteric fractures of the femur (AFFs). The objective of this article is to review this evidence, while presenting the current available strategies for the management of AFFs.
methodsWe present an evaluation of current literature relating to the pathogenesis and treatment of AFFs in the context of bisphosphonate use.
resultsSix broad themes relating to the pathogenesis and management of bisphosphonate-related AFFs are presented. The key themes in fracture pathogenesis are: bone microdamage accumulation; altered bone mineralisation and altered collagen formation. The key themes in fracture management are: medical therapy and surgical therapy. In addition, primary prevention strategies for AFFs are discussed.
conclusionsThis article presents current knowledge about the relationship between bisphosphonates and the development of AFFs, and highlights key areas for future research. In particular, studies aimed at identifying at-risk subpopulations and organising surveillance for those on long-term therapy will be crucial in both increasing our understanding of the condition, and improving population outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.